Literature DB >> 21083653

Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients.

Tommasina Guglielmelli, Maria Teresa Petrucci, Giuseppe Saglio, Antonio Palumbo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21083653     DOI： 10.1111/j.1365-2141.2010.08416.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

Review 1.  What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma.

Authors:  Bruno Almeida Costa; Tarek H Mouhieddine; Joshua Richter
Journal:  Target Oncol       Date:  2022-06-30       Impact factor: 4.864

2.  Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma.

Authors:  Nilanjan Ghosh; Noah Tucker; Marianna Zahurak; Jocelyn Wozney; Ivan Borrello; Carol Ann Huff
Journal:  Am J Hematol       Date:  2014-04-26       Impact factor: 10.047

3.  A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial.

Authors:  Tatsuo Ichinohe; Yoshiaki Kuroda; Shinichiro Okamoto; Kosei Matsue; Shinsuke Iida; Kazutaka Sunami; Takuya Komeno; Kenshi Suzuki; Kiyoshi Ando; Masafumi Taniwaki; Kensei Tobinai; Takaaki Chou; Hitomi Kaneko; Hiromi Iwasaki; Chie Uemura; Hiromi Tamakoshi; Mohamed H Zaki; Thomas Doerr; Shotaro Hagiwara
Journal:  Exp Hematol Oncol       Date:  2016-04-18

4.  Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Authors:  Shinsuke Iida; Masashi Wakabayashi; Kunihiro Tsukasaki; Kenichi Miyamoto; Dai Maruyama; Kazuhito Yamamoto; Yoshifusa Takatsuka; Shigeru Kusumoto; Junya Kuroda; Kiyoshi Ando; Yoshitaka Kikukawa; Yasufumi Masaki; Miki Kobayashi; Ichiro Hanamura; Hiroaki Asai; Hirokazu Nagai; Kazuyuki Shimada; Norifumi Tsukamoto; Yoshiko Inoue; Kensei Tobinai
Journal:  Cancer Sci       Date:  2018-04-17       Impact factor: 6.716
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.